These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23748351)

  • 1. Product quality considerations for mammalian cell culture process development and manufacturing.
    Gramer MJ
    Adv Biochem Eng Biotechnol; 2014; 139():123-66. PubMed ID: 23748351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a cell culture manufacturing process using quality by design (QbD) principles.
    Marasco DM; Gao J; Griffiths K; Froggatt C; Wang T; Wei G
    Adv Biochem Eng Biotechnol; 2014; 139():93-121. PubMed ID: 23828505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
    Chen D
    Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equipment for large-scale mammalian cell culture.
    Ozturk SS
    Adv Biochem Eng Biotechnol; 2014; 139():69-92. PubMed ID: 24429549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade
    Melsheimer R; Calmann M; DeRitis A; Philip V; Van Gog F; Doolittle L; Goyal K; Neblock D
    BioDrugs; 2018 Oct; 32(5):405-414. PubMed ID: 30143982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
    Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
    J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.
    Eon-Duval A; Broly H; Gleixner R
    Biotechnol Prog; 2012; 28(3):608-22. PubMed ID: 22473974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.
    Looby M; Ibarra N; Pierce JJ; Buckley K; O'Donovan E; Heenan M; Moran E; Farid SS; Baganz F
    Biotechnol Prog; 2011; 27(6):1718-29. PubMed ID: 21948302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of the scan statistic for quality control in blood product manufacturing.
    Lachenbruch PA; Foulkes MA; Williams AE; Epstein JS
    J Biopharm Stat; 2005; 15(2):353-66. PubMed ID: 15796300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Konstantinov KB; Cooney CL
    J Pharm Sci; 2015 Mar; 104(3):813-20. PubMed ID: 25417595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
    Ravisé A; Cameau E; De Abreu G; Pralong A
    Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Quality by Design to the characterization of the cell culture process of an Fc-Fusion protein.
    Rouiller Y; Solacroup T; Deparis V; Barbafieri M; Gleixner R; Broly H; Eon-Duval A
    Eur J Pharm Biopharm; 2012 Jun; 81(2):426-37. PubMed ID: 22426134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-by-Design approach to monitor the operation of a batch bioreactor in an industrial avian vaccine manufacturing process.
    Largoni M; Facco P; Bernini D; Bezzo F; Barolo M
    J Biotechnol; 2015 Oct; 211():87-96. PubMed ID: 26216182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics.
    Ishii-Watabe A; Hirose A; Katori N; Hashii N; Arai S; Awatsu H; Eiza A; Hara Y; Hattori H; Inoue T; Isono T; Iwakura M; Kajihara D; Kasahara N; Matsuda H; Murakami S; Nakagawa T; Okumura T; Omasa T; Takuma S; Terashima I; Tsukahara M; Tsutsui M; Yano T; Kawasaki N
    AAPS PharmSciTech; 2015 Oct; 16(5):993-1001. PubMed ID: 26288941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.